Saol Therapeutics
↗Roswell, USA
Saol Therapeutics is a privately held, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapies for central nervous system (CNS) disorders and rare diseases. Founded in 2015, the company has established a robust presence in the neurology and orphan disease sectors, with operations spanning Roswell, Georgia; Dublin, Ireland; and Hamilton, Bermuda.
In early 2022, Saol underwent a significant strategic shift by divesting its commercialized baclofen franchise (including Lioresal and Lyvispah) to Amneal Pharmaceuticals for approximately $83.5 million. This move allowed the company to focus exclusively on its late-stage development pipeline, particularly its programs for Pyruvate Dehydrogenase Complex Deficiency (PDCD) and chronic pain management. The company is backed by prominent private equity firms, including Avego Management and DFW Capital Partners.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CNS and Rare Disease Therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$20M
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$66.7M
Investors:Avego Management, DFW Capital Partners, CD Private Equity
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 / NDA Review
Modalities:Small molecule, Perineural injection
Active Trials:3
Trial Phases:Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Saol International Development Ltd
Key Partnerships:Medosome Biotec (Companion diagnostic for SL-1009), Amneal Pharmaceuticals (Divestiture partner)
COMPETITION
Position:Niche Player
Competitors:Voyager Therapeutics, TauRx Pharmaceuticals, Neurogene, Neurolixis, NeuroNascent
LEADERSHIP
Key Executives:
David Penake - CEO
Virinder Nohria - Chairman
Sharon Hamm - SVP, Technical Operations
Scientific Founders:Virinder Nohria
Board Members:Virinder Nohria, DeVer F. Warner, James Flexner, John Devane, Thomas Vandervort
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Saol Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.